| Followers | 238 |
| Posts | 15504 |
| Boards Moderated | 1 |
| Alias Born | 03/29/2014 |
Saturday, April 01, 2017 2:29:23 PM
Jason J. Mendro of Gibson Dunn & Crutcher is the lawyer for the defendants in the Lerner case.
Mendro is also the lawyer for NWBO and Cognate in the Yonemura case.
Scott R. Haiber is the attorney for LP, Toucan et al for the Yonemura case.
I'm not sure who their attorney is for NWBO on the Terrice Tharp case.
Side Note:
I guess Nicholas Porritt (he's British) is the attorney for Christine Yonemura. I had indicated I didn't think her attorney was on that conference call I listened in on.
I thought he was the attorney for NWBO - I guess that mistake comes from the fact that I am a shareholder just like all of you including China, lol, and I got mixed up on who was who.
Nicholas Porritt
https://www.zlk.com/attorneys/nicholas-i-porritt
He's also qualified as a Solicitor of the Senior Courts of England and Wales. So if anyone wants to prosecute those behind Phase 5, I suppose he'd be qualified to represent them.
Mendro is also the lawyer for NWBO and Cognate in the Yonemura case.
Scott R. Haiber is the attorney for LP, Toucan et al for the Yonemura case.
I'm not sure who their attorney is for NWBO on the Terrice Tharp case.
Side Note:
I guess Nicholas Porritt (he's British) is the attorney for Christine Yonemura. I had indicated I didn't think her attorney was on that conference call I listened in on.
I thought he was the attorney for NWBO - I guess that mistake comes from the fact that I am a shareholder just like all of you including China, lol, and I got mixed up on who was who.
Nicholas Porritt
https://www.zlk.com/attorneys/nicholas-i-porritt
He's also qualified as a Solicitor of the Senior Courts of England and Wales. So if anyone wants to prosecute those behind Phase 5, I suppose he'd be qualified to represent them.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
